Thermo Fisher Scientific Inc., Merck KGaA, and Agilent Technologies, Inc. Dominated the Asia-Pacific ADME Toxicology Testing Market in 2020

Asia-Pacific ADME Toxicology Testing Market is expected to grow at a CAGR of 11.3% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-adme-toxicology-testing-market

Asia-Pacific toxicology testing market is highly consolidated and includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

Major players operating in the Asia-Pacific toxicology testing market are introducing a wide range of products along with launching new products and adopting strategic initiatives, such as acquisitions, agreements, business expansions, and awards and recognitions, into the market. This will help them maximize their sales with enhanced product portfolio.

For instance:

  • In October 2020, Thermo Fisher Scientific Inc. expanded its direct to patient clinical trials service offering. This expansion has enhanced the portfolio of the company, providing it lucrative growth opportunities.

Thermo Fisher Scientific Inc. is the dominating player in the Asia-Pacific toxicology testing market. Other key players operating in the market are Merck KGaA, Agilent Technologies, Inc., Corning Incorporated, Lonza, Charles River Laboratories, Bio-Rad Laboratories, Inc., Promega Corporation, LABCYTE INC., Takara Bio Inc., PromoCell GmbH, BioIVT, AAT Bioquest, Inc., and others.

Asia-Pacific ADME Toxicology Testing Market Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is headquartered in Massachusetts, U.S. and was founded in 1960. The company manufactures scientific instruments, consumables, and chemicals. It offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and others. The company operates its business through several business segments that are life science solutions, analytical instruments, speciality diagnostics, and laboratory products and services in which life science solutions is the market focused product. The company has a wide range of product categories, such as life sciences, industrial and applied science, clinical diagnostics, lab solutions, and digital solutions, in which industrial and applied science is the market focused category. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In October 2020, Thermo Fisher Scientific Inc. expanded its direct to patient clinical trials service offering. This expansion has enhanced the portfolio of the company, providing it lucrative growth opportunities

The company has wide presence across North America, Europe, Asia-Pacific South America, and Middle East and Africa. It also has various subsidiary companies such as Thermo Trace Limited (Australia), Thermo Electron A/S (France), Jouan Limited (England), Jouan Nordic AS (Denmark), JSC Thermo Electron (Russia), and others.

Merck KGaA

Merck KGaA was founded in 1668. The company’s headquarter is in Darmstadt, Germany. It is a science and technology company, which is engaged in the manufacturing of pharmaceutical and chemical products. The company has a wide range of product and service categories, such as healthcare, life science, and electronics, in which life science is the market focused product. The company is attaining lucrative growth through several strategic initiatives.

  • In May 2021, Merck KGaA, announced the extension of its ongoing collaboration with BioMed X, Heidelberg, Germany. As a result of this successful collaboration, multiple innovative discovery projects in new research areas have been started at Merck.

The company has wide presence across North America, Europe, Middle East and Africa, Asia-Pacific and Latin America. It also has various subsidiary companies such as Sigma-Aldrich (U.S.), MilliporeSigma (U.S.), Merck S.A. (France), Merck Ltd. (Japan), Asceneuron SA (Switzerland), and others.

Agilent Technologies, Inc.

Agilent Technologies, Inc. is headquartered in Delaware, the U.S., and founded in 1999. The company provides its products and services on five markets, food, environmental and forensics, pharmaceutical and diagnostics, chemical and energy, and research. It has various product and service categories that are xCELLigence RTCA Cardio- Cardiomyocyte Contractility, xCELLigence RTCA CardioECR Cardiomyocyte Contractility & Electrical Activity, xCELLigence RTCA ePacer- Cardiomyocyte Pacing, RTCA Cardio Software, RTCA CardioECR Software, and RTCA EPacer Software, in which Cell Analysis is the market focused product. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In April 2021, Agilent Technologies Inc. announced that it has acquired Resolution Bioscience, which is a leader in the development and commercialization of next generation sequencing based precision oncology solutions

The company has presence across U.S., Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the UK. It also has various subsidiary companies such as Agilent Technologies Mauritius Limited (Mauritius), Agilent Technologies Japan, Ltd. (Japan), Agilent Technologies Canada Inc. (Canada), Agilent Technologies France S.A.S. (France), Agilent Technologies Australia Pty Ltd. (Australia), and others.